Brachytherapy for clinically localized prostate cancer

Abstract

Prostate brachytherapy is an effective treatment option for clinically organ‐confined prostate carcinoma. Observed 5‐ and 10‐year follow‐up have documented prostate‐specific antigen (PSA) levels that were comparable to published radical prostatectomy series and were better than several published external‐beam radiation series. Between January 1987 and June 1988, a total of 152 consecutive patients with Stage T1 to T3 low to high Gleason grade prostate cancer were studied at Northwest Hospital in Seattle, Washington. Patients' median age was 70 years (range, 53 to 92 years). All patients received Iodine‐125 prostate brachytherapy with or without a 45 Gy dose of external‐beam radiation. The average preoperative PSA, clinical stage, and prostate needle biopsy Gleason sum were 11 ng/ml, T2, and (5), respectively, and were known in all but five patients. PSA follow‐up, clinical examination, and biopsy results judged disease‐free survival at 5 and 10 postoperative years. Elevation of PSA above 0.5 ng/ml or a positive biopsy or a positive bone scan was considered treatment failure. The authors provide an historical review of prostate brachytherapy in conjunction with up‐to‐date implant techniques and long‐term outcome results. Semin. Surg. Oncol. 18:45–51, 2000. © 2000 Wiley‐Liss, Inc.

Nuclear Data Relevant to the Production of Radioiodine I-123, I-125 by Indirect Route and Medical Applications

“…One of the most common effective medical applications of Iodine-125 is its involvement in the treatment of prostate cancer. Iodine-125 is used as nuclear imaging tracer to evaluate the anatomic and physiologic function [6]. When I-125 is used therapeutically, it is encapsulated in Titanium seeds and implanted in the area of the tumor, where it remains.…”

Impact of a novel neoadjuvant and adjuvant hormone‐deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy

“…adical prostatectomy, 1,2 external beam radiotherapy, and brachytherapy [3][4][5][6][7][8] are widely used treatments for patients with clinically localized prostate carcinoma. Proponents of prostate brachytherapy associate this treatment with a better quality of life (QOL).…”

“…At OSU, from February 1997 through September 2000, 165 men with clinical stage T1c-T2bN0M0 adenocarcinoma of the prostate (UICC/ AJCC 1997classification system 25 ) were treated with BTM alone. The implant procedure was the same at both institutions, 6 with all patients receiving a Pd103 implant dose of 115 grays (Gy).…”

Rectal Ulceration as a Result of Prostatic Brachytherapy: A New Clinical Problem

“…Disease-specific survival 10 years after treatment is as high as 98 percent. 8 Published complications are few with urinary system complications being more frequent than rectal complications. A series from Memorial Sloan-Kettering Cancer Center cited the development of rectal ulcers in 5 of 92 patients treated with prostatic brachytherapy.…”